Q-omics provides the consensus-scored YWHAH profile across patient tissues and cancer cell-line models. YWHAH expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, YWHAH is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, YWHAH protein abundance shows 25,876 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where YWHAH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YWHAH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YWHAH survival associations across molecular data types. YWHAH RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YWHAH RNA expression–survival associations across cancer types. High YWHAH expression shows unfavorable associations in ACC, UVM, LIHC, MESO, HNSC and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for YWHAH RNA expression.
This table summarizes YWHAH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YWHAH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YWHAH shows higher tumor expression in KIRC, HNSC, LIHC, KIRP, STAD and BRCA. The KIRC box plot shows higher YWHAH RNA expression in tumor versus normal tissue (log2 FC = +1.235, t-test p < 0.001).
This table shows molecular features associated with YWHAH in patient tissues and cancer cell lines. In patient samples, YWHAH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, YWHAH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
